Biohit Oyj - Decisions of extraordinary general meeting

Decision made at Biohit Oyj's Extraordinary Shareholder Meeting

Biohit Oyj
Company Announcement
23.11.2011 05:25 pm

A decision was made at Biohit Oyj's Extraordinary Shareholder Meeting on
Wednesday 23 November 2011 to approve the agreement between Biohit Oyj and
Sartorius Lab Holding GmbH on the sale of Biohit's liquid handling business to
Sartorius for EUR 68 million and to authorise the Board of Directors to close
the deal. The transaction is subject to approval by the authorities. The deal
is expected to be finalised by the end of 2011. The terms of the deal were
explained in more detail in a stock exchange release dated 26 October 2011. 

All decisions taken at the shareholder meeting were unanimous. The minutes of
the meeting will be available to shareholders, no later than two weeks after
the meeting, on the company website and at Biohit's headquarters at Laippatie
1, 00880 Helsinki. 


For more information, please contact:
Osmo Suovaniemi
Chairman of the Board of Directors
Tel. +358 40 745 5605
osmo.suovaniemi@biohit.com

Distribution:
NASDAQ OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
 www.biohit.com


About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission is crystallised by its motto “Innovating for Health”.
The company assumes social responsibility by producing innovations, new
technologies and analysis systems for use in medicine, research institutions
and industry. These products help to promote research and diagnostics, while
improving quality of life by preventing disease, human suffering and financial
loss. Biohit also seeks to innovate and develop the marketing and availability
of its products and services, in order to ensure its profitable growth and
ability to pay dividends. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations. These can be used to
develop safe and cost-effective liquid handling solutions for laboratory work,
as well as diagnostic tests for the early detection and prevention of diseases
of the gastrointestinal tract. 

Biohit has two business segments: liquid handling and diagnostics. Liquid
handling products include electronic and mechanical pipettes, disposable tips,
and pipette maintenance and calibration services for research institutions,
healthcare and industrial laboratories. 

The diagnostics business comprises products and analysis systems for the
prevention and early diagnosis of gastrointestinal diseases, such as the
blood-sample based GastroPanel examinations for the diagnosis of stomach
illnesses and associated risks, quick tests for the diagnosis of lactose
intolerance and H. pylori infection in connection with gastroscopy, and the
ColonView examination for the early detection of intestinal bleeding that
indicates a risk of colorectal cancer. Acetium reduces the amount of
carcinogenic acetaldehyde in an anacidic stomach. 

The Biohit Group employs around 440 people. The company is headquartered in
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,
India, China, Japan and the USA. The company also has a representative office
in Singapore. Biohit's products are sold through about 200 distributors in 70
countries. 

Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group and is traded under the code BIOBV
(www.biohit.com/investors). 

Read more at www.biohit.com